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An estimate of the prevalence of epilepsy in 
Sub–Saharan Africa: A systematic analysis
Background Epilepsy is a leading serious neurological condition 
worldwide and has particularly significant physical, economic and 
social consequences in Sub–Saharan Africa. This paper aims to con-
tribute to the understanding of epilepsy prevalence in this region and 
how this varies by age and sex so as to inform understanding of the 
disease characteristics as well as the development of infrastructure, 
services and policies.
Methods A parallel systematic search of Medline, Embase and Glob-
al Health returned 32 studies that satisfied pre–defined quality cri-
teria. Relevant data was extracted, tabulated and analyzed. We mod-
elled the available information and used the UN population figures 
for Africa to determine the age–specific and overall burden of epi-
lepsy.
Results Active epilepsy was estimated to affect 4.4 million people in 
Sub–Saharan Africa, whilst lifetime epilepsy was estimated to affect 
5.4 million. The prevalence of active epilepsy peaks in the 20–29 age 
group at 11.5/1000 and again in the 40–49 age group at 8.2/1000. 
The lowest prevalence value of 3.1/1000 is seen in the 60+ age group. 
This binomial pattern is also seen in both men and women, with the 
second peak more pronounced in women at 14.6/1000.
Conclusion The high prevalence of epilepsy, especially in young 
adults, has important consequences for both the workforce and com-
munity structures. An estimation of disease burden would be a ben-
eficial outcome of further research, as would research into appropri-
ate methods of improving health care for and tackling discrimination 
against people with epilepsy.
At the United Nations high–level meeting on the prevention and control 
of non–communicable diseases (NCDs) in 2011, there was a general con-
sensus that NCDs are already the universal leading causes of death, and 
that their burden is rapidly increasing [1]. By 2030, NCDs are expected 
to account for the death of 52 million people [2]. Low– and middle–in-
come countries (LMICs) that lack the resources and infrastructure to cope 
with the diseases are expected to bear a disproportionate amount of the 
disease burden [3,4]. Accurate estimates of the burden of NCDs are vital 
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to the monitoring of diseases and policy planning, but cur-
rently lacking in many of these countries [5].
Epilepsy is the most common NCD of neurological origin 
that affects approximately 50 million people worldwide 
[1,6]. Unlike many NCDs that are related to aging, epilep-
sy is more prevalent in children and young adults [7]. Over 
85% of epilepsy cases are found in LMICs [8], most of 
which occur in poor regions of Africa that have the great-
est number of the world’s population under the age of 15 
[9]. Epilepsy severely affects the quality of life for people. 
The condition is highly stigmatised because of the com-
monly held misconception that epilepsy is contagious and 
the negative meanings attached to its outward manifesta-
tion, seizures [8,10,11]. In many parts of Sub–Saharan Af-
rica (SSA), epilepsy continues to be associated with witch-
craft [11-13]. For these reasons, people with epilepsy are 
often socially ostracised, have reduced life chances in terms 
of employment and marriage [8], and are prone to having 
poorer self–esteem and other mental health conditions 
such as anxiety and depression [10]. Yet, it is known that 
about 70% of people with epilepsy could lead full, seizure–
free lives if treated [14]. Despite this, over 90% of people 
in SSA with epilepsy do not receive treatment [14]. With-
out treatment, people with epilepsy are at high risk of in-
jury especially from burns should seizures occur because 
of tasks as cooking over an open fire or playing near pit 
fires [15]. Some background details on the condition are 
provided in Box 1 [15-35].
In the only systematic review to date based on the analysis 
of 28 studies published, Preux and Druet-Cabanac esti-
mated the median prevalence of epilepsy in SSA to be 
15/1000 [15], but this estimate is simply a median value 
from door–to–door studies in several countries. No studies 
have yet attempted to provide age and sex–specific preva-
lence of epilepsy for SSA. By way of systematic review, the 
aims of this study were thus: (i) to provide an updated es-
timate for the overall prevalence of epilepsy in SSA; (ii) to 
give sex and age–specific breakdown for the epilepsy prev-
alence for SSA; and (iii) to assess the limitations of the avail-
able data. It is hoped that the findings of this study would 
help improve the evidence base for informing health poli-
cy regarding epilepsy in SSA.
METHODS
Search strategy
Initially, a literature search was carried out based on the 
terms ‘epilepsy’ AND ‘Africa’ to scope out the information 
available. The final literature review of Medline, Embase 
and Global Health was undertaken on 6 March 2012. Ta-
ble 1 shows the Medline search terms. Embase and Glob-
al Health were searched with terms adjusted as necessary, 
Table 1 Medline search strategy
1 “africa south of the sahara”/ or africa, central/ or cameroon/ or cen-
tral african republic/ or chad/ or congo/ or “democratic republic of 
the congo”/ or equatorial guinea/ or gabon/ or africa, eastern/ or 
burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ 
or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ 
or angola/ or botswana/ or lesotho/ or malawi/ or mozambique/ or 
namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or 
africa, western/ or benin/ or burkinafaso/ or cape verde/ or cote 
d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or libe-
ria/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or si-
erra leone/ or togo/
2 comoros/ or madagascar/ or mauritius/ or reunion/ or seychelles/
3 mayotte.mp.
4 (sao tome and principe).mp. [mp = title, abstract, original title, 
name of substance word, subject heading word, protocol supple-
mentary concept, rare disease supplementary concept, unique 
identifier]
5 saint helena.mp.
6 prevalence/
7 prevalen*.tw.
8 incidence/
9 incidence*.tw
10 (disease adj3 burden*).tw.
11 epilep*.tw.
12 epilepsy/ or epilepsies, myoclonic/ or myoclonic epilepsies, pro-
gressive/ or lafora disease/ or merrf syndrome/ or unverricht-lund-
borg syndrome/ or myoclonic epilepsy, juvenile/ or epilepsies, par-
tial/ or epilepsy, complex partial/ or epilepsy, frontal lobe/ or 
epilepsy, partial, motor/ or epilepsy, partial, sensory/ or epilepsy, 
rolandic/ or epilepsy, temporal lobe/ or epilepsy, benign neonatal/ 
or epilepsy, generalized/ or epilepsy, absence/ or epilepsy, tonic-
clonic/ or spasms, infantile/ or epilepsy, posttraumatic/ or epilepsy, 
reflex/ or landau-kleffner syndrome/ or seizures/ or seizures, febrile/ 
or status epilepticus/ or epilepsiapartialis continua/
13 1 or 2 or 3 or 4 or 5
14 6 or 7 or 8 or 9 or 10
15 11 or 12
16 13 and 14 and 15
17 limit 20 to yr = ”1980-Current”
as shown in Online Supplementary Document and yielded 
381 and 165 results respectively. Countries were included 
under the heading Sub–Saharan Africa based on the UN 
data on geographical regions and composition [36]. The 
searches were limited to articles published between 1980 
and the search date, yielding 701 results total. This limit 
was put in place to ensure that the results would be relevant 
to the current situation in SSA. No other limits were placed 
on the search.
Results of the 3 searches were then combined and dupli-
cates removed, yielding 480 papers. The titles and abstracts 
of these 480 papers were then analysed and included if they 
indicated a value for prevalence in the abstract or clearly 
stated that a value would likely be present in the text. This 
generated 83 relevant papers (Figure 1). The full text ar-
ticles were then searched to assess whether each of the 
studies met the full selection criteria (see Box 2 for details 
of the selection criteria). Bibliographies of the selected ar-
ticles and relevant review papers were searched to identify 
any further papers not generated by the literature searches.V
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Data extraction and analysis
The data from 31 published articles that met the criteria 
were extracted and tabulated. Age and gender–specific 
prevalence data were extracted along with the size of the 
population that provided a denominator for the prevalence 
value. Available data regarding the types of seizures expe-
rienced by the participants were also extracted. Relevant 
data regarding the seizure types of those with active epi-
lepsy were found in 15 papers and were categorised based 
on the International League Against Epilepsy (ILAE) clas-
Box 1 Aetiology and treatment of epilepsy
Epilepsy is diagnosed when an individual experiences multiple seizures, where a seizure is disordered dis-
charging of cerebral neurones [14]. This can occur throughout the brain, causing a generalised seizure, or 
be confined to one area, causing a partial seizure. These seizure types are further classified to include, amongst 
others, absence and atonic seizures. The likelihood of an individual to have seizures depends upon their 
seizure threshold, which can be lowered when the neurons develop a tendency to be hyperexcitable. This 
can result from a variety of risk factors [14].
Central nervous system infections
Epilepsy can result from CNS infection by viruses such as measles, secondary to bacterial meningitis or 
encephalitis, fungi and parasites, most commonly neurocysticercosis (NCC) [14]. A significant associa-
tion has been recognised between cysticercosis, parasitic infection with Taeniasolium tapeworm larvae, 
and epilepsy [16,17]. The prevalence of cysticercosis is higher in developing countries where sanitation 
facilities are less advanced and vectors include pigs, food and faecal contamination on the water supply. 
Epilepsy has been shown to be more frequent in areas highly endemic for onchocerciasis [18].
Malaria is highly prevalent in many areas of SSA [19], and contracting Plasmodium falciparum malaria in 
childhood is associated with nearly a 50% chance of developing cerebral malaria and a 37.5% chance of 
developing epilepsy [20]. Other infectious risks include meningitis and encephalitis [14].
Birth complications
In Sub–Saharan Africa, two thirds of women requiring emergency obstetric care are unable to receive it 
[21]. Untreated adverse perinatal complications are associated with a increased risk of suffering a period 
of hypoxic–ischaemic encephalopathy and subsequently developing epilepsy [22,23].
Febrile convulsions
Children under the age of 5 may also experience febrile convulsions in the event of high fever and, whilst 
this is not considered epilepsy, a small number of these children go on to develop epilepsy [14]. There is 
a recognised association between febrile seizures and epilepsy in Sub–Saharan Africa [23,24]. The defi-
nition of epilepsy used in this paper refers to seizures unprovoked by any immediate identified cause 
[25], and therefore febrile convulsions themselves are excluded from calculations.
Head injury
A common cause of childhood epilepsy is perinatal head injury. Later in life, a traumatic head injury or 
surgery may also result in epilepsy. It has been noted that even mild head trauma leads to an increased 
risk of epilepsy and this risk is present for more than 20 years following the injury [26]. Indeed, the study 
found the most significant risk of developing epilepsy to be associated with war injuries. In SSA head in-
juries have been identified as risk factors for epilepsy [24], and in this region road traffic accidents and 
violent conflict are important the risk factors for head injury [15].
A number of other risk factors exist including tumours [15], vascular disease and potentially brain stress-
ors: malnutrition and low economic conditions [27]. A proportion of people with epilepsy also have no 
identifiable cause, for example in Cameroon 29% had idiopathic epilepsy [28]. There are also several 
known genetic causes of epilepsy [29] and, although a genetic mutation cannot be identified in many in-
dividuals with epilepsy, a family history of epilepsy is often present [30].
Treatment options
Phenobarbitone is most commonly used antiepileptic drug in SSA [16,31] and is widely affordable [32], 
despite widespread poverty, as it costs only US$ 5 per person per year [33,34]. However, there is a 65–95% 
treatment gap [10]. In Benin, 64% of children were not being treated and 50% of those who were received 
treatment from traditional healers [34]. In addition, this situation, where a large number of people with 
epilepsy do not have access to any treatment at all, is likely to result in feelings of helplessness and frustra-
tion. Given that 70% of people will epilepsy could lead full, seizure–free lives if treated [14,35], it is im-
portant to consider the role that AEDs could play in decreasing this association and therefore decreasing 
the likelihood that people with epilepsy move into lower socioeconomic groups.V
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sification of seizures [14,25]. For each study, mean age was 
calculated for each available subset of data with prevalence. 
If an age group had two boundaries, the median of the 
range was used. If an age group contained a lower age lim-
it and older (eg, ‘60 years or more’), United Nations Popu-
lation Division’s (UNPD) population estimates for the 
country and the year in which the study was conducted 
were used to estimate the mean age. Where there was an 
absence of a denominator, mean age was calculated for the 
amount of data for which there was a denominator (usu-
ally the whole study). This last rule also applies to age 
bands with only one given boundary.
The mean age of each data subset, its corresponding prev-
alence, and sample size were combined into a graph to il-
lustrate the pattern of epilepsy prevalence across the age 
range of 0 to 60+. Each data point is represented by a circle 
proportional to the sample size. Ten–year age groups were 
used as they corresponded with the age groupings of the 
majority of the studies. The weighted mean of the preva-
lence for each age group and their 95% confidence interval 
were also calculated. The weighted mean of the prevalence 
for each age group was then multiplied by the correspond-
ing population estimate by the UNPD for SSA for the 
year2010 [36]. Data for the year 2010 was used because 
we found no statistically significant changes in standard-
ized prevalence of epilepsy over the period 1980–2012, 
while the largest and most reliable studies were conducted 
in the past decade. This provided an estimation of the num-
ber of people with active and lifetime epilepsy in SSA over-
all, as well as age and gender breakdown. For the data ex-
tracted on seizure classification, the total number of each 
seizure type found in all the relevant studies were calcu-
lated, and then divided by the total number of people with 
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Figure 1 Search strategy.
Box 2 Selection criteria
Inclusion criteria
– All age ranges
– Both sexes
– All countries in Sub–Saharan Africa
–   Studies conducted to examine the epidemiology of ep-
ilepsy
– Population based studies
–   Measure of disease must include a numerator and de-
nominator
–   Clear time period of study (studies were included with-
out this factor, if all other criteria were satisfied, and 
the year of publication was used instead)
Exclusion criteria
– Health service or health record based studies
– Studies published before 1980
–   Studies conducted in a population with characteristics 
that clearly indicated it to be unrepresentative of the 
national population
– Febrile convulsions and provoked seizures included in 
the estimation of epilepsy prevalence
Quality criteria
Clear case definition and diagnosis of epilepsy [14,25]:
Epilepsy: condition characterized by recurrent (two or more) 
epileptic seizures, unprovoked by any immediate identified 
cause. Multiple seizures occurring in a 24–h period are con-
sidered a single event. An episode of status epilepticus is 
considered a single event. Individuals who have had only 
febrile seizures or only neonatal seizures as herein defined 
are excluded from this category [25].
‘Active’ epilepsy: a prevalent case of active epilepsy is defined 
as a person with epilepsy who has had at least one epileptic 
seizure in the previous 5years, regardless of antiepileptic 
drug (AED) treatment. A case under treatment is someone 
with the correct diagnosis of epilepsy receiving (or having 
received) AEDs on prevalence day [25].
Diagnosis: “Diagnosis of epilepsy is essentially clinical, based 
on a bona fide history of epileptic seizures. Diagnosis should 
be confirmed by a health professional with expertise in epi-
lepsy, using available medical history, seizure description, 
and neurologic examination. Standardized study methods 
should be used to obtain information about the above three 
diagnostic elements, and standardized criteria should be 
used for their interpretation. If available, EEG records and 
other diagnostic tools should also be used, but lack of these 
instruments should not preclude the diagnosis of epilepsy. 
EEG contributes but does not always confirm a diagnosis of 
epilepsy: An abnormal EEG must not be considered as a req-
uisite for inclusion since it could be normal (or indicate non-
specific abnormalities) in epileptic subjects. On the other 
hand, an abnormal EEG (with epileptiform abnormalities), 
after an isolated seizure, could suggest classification of the 
seizure as epilepsy” [25].V
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epilepsy. This provided a percentage value to represent the 
proportion of people with epilepsy likely to experience 
each type of seizure in SSA.
Subsequent to the literature search, two articles in press 
were found on Scopus and were included in the review. A 
study by Prischich et al was excluded from the final analy-
sis because it was conducted in an area with high levels of 
onchocerciasis and contains outlier data that is not repre-
sentative of the general population [37]. Osuntokun et al 
was removed as it was published in 1982 and gave no date 
for when the study was conducted, but this was likely be-
fore 1980 and therefore not relevant to this review [38].
RESULTS
Study characteristics
Table 2 shows the main characteristics of the studies re-
tained for our final analysis. They included countries from 
East, West, Middle and Southern Africa, and therefore can 
be considered reasonably representative of SSA as a whole 
(Figure 2). Only 9.4% of studies were conducted on less 
than 1000 individuals, 53.1% were conducted on more 
than 5000 individuals. There were 59.4% of the studies 
conducted in rural areas; as studies conducted in both ru-
ral and urban populations have shown that epilepsy is 
more prevalent in rural areas, the overrepresentation of ru-
ral studies in this review might represent a slight bias to-
wards higher prevalence [30,39]. Figure 3 shows that the 
studies included in the analysis were all published after 
1980, with two–thirds of them published after 2000. The 
Estimating incidence of epilepsy in Sub–Saharan Africa
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Figure 2 Map showing the prevalence of epilepsy by country in 
Sub–Saharan Africa (adapted from http://www.worldatlas.com/
webimage/countrys/africa/afoutl.htm).
Table 2 Study characteristics (see Online Supplementary 
Document for full table of study characteristics)
Characteristics No. studies
Country:
Benin 3
Burkina Faso 2
Cameroon 1
DRC 1
Ethiopia 1
Gabon 1
Gambia 1
Kenya 3
Liberia 1
Madagascar 1
Nigeria 3
Rwanda 1
Senegal 1
South Africa 1
Tanzania 4
Togo 3
Uganda 2
Zambia 1
Sample size:
<1000 3
1000–4999 11
5000–9999 7
10 000–49 999 6
50 000–200 000 4
Setting:
Rural and urban 1
Nationwide 2
Rural 19
Semirural 2
Urban 6
Year of study:
Unknown 6
1980–1984 2
1985–1989 5
1990–1994 1
1995–1999 6
2000–2004 7
2005–2009 4
2010–2012 1
Study design:
Cross–sectional 4
Door–to–door 22
Random sampling 3
Key informant 2
Unclear 1
Figure 3 The distribution of studies according to the year of 
publication.
majority of the studies (68.8%) were door–to–door sur-
veys, which are consistent with the ‘gold standard’ research 
for epilepsy prevalence estimates [40].
Case definitions
The ILAE Guidelines for Epidemiological Studies on Epi-
lepsy [25] describe the diagnosis as ‘essentially clinical’. 
They recognise that EEG facilities are not always available, V
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and note that EEG is not required for diagnosis. All studies 
included in this review comply with the ILAE guidelines as 
they each provide an appropriate set of criteria for clinical 
symptoms and diagnosis of epilepsy based upon a fitting 
history. Active epilepsy was diagnosed if an individual had 
at least one of their multiple seizures in the previous 5 years. 
Whilst the studies all had appropriate conditions, many had 
more stringent criteria for active epilepsy: 34.4% only in-
cluded people who had had seizures within the last year, 
15.6% in 2 years, 31.3% in 3 years and 25% in 5 years. This 
is likely to have led to an underestimation of the prevalence 
of active epilepsy. When these studies were separated based 
upon different definitions of active epilepsy, the median 
prevalence for each category was 14.4/1000 for studies re-
quiring a seizure to have taken place in the last 1 year, 10.2 
for 2 years, 38.3 for 3 years and 8.6 for 5 years. Table 3 
summarizes case definitions used in the retained studies. It 
shows that studies generally included a definition of active 
epilepsy, usually defined as a seizure within one or five 
years. Only five studies did not give details of the question-
naire used for case identification, while only six studies did 
not state that a neurologist confirmed the diagnosis.
Active epilepsy prevalence in the 
population of SSA
The data points represented by a hollow blue circle in Fig-
ure 4 show the mean age of either a subset, or the entire 
study population, and the corresponding prevalence for 
Table 3 Epilepsy definitions and diagnostic criteria used by included studies
Authors Neurol-
ogist EEG
At least one 
seizure within 
previous year Questionnaires used Sensitivity Specificity
1 2 3 5 Life-
time
Case confirmed by neurologist; EEG used:
Balogou et al [33] Y Y + + PAANS (2000) [41] 95% 65.10%
Balogou et al [33] Y Y + PAANS (2000) [41] 95% 65.10%
Burton et al [22] Y Y + Based on Placencia et al, 1992 [42] 98% 92%
Mung'ala-Odera et al [23] Y Y + TQQ (Durkin, et al., 1994) [43] 100% 93%
Ndoye et al [44] Y Y + GCAE (Wang et al, 2003) [45] 100% 78.50%
Osuntokun et al [38] Y Y + Based on Osuntokun et al, 1987 [38] 91% 85%
Tekle-Haimanot et al [46] Y Y + Based on Osuntokun et al, 1987 [38] 91% 85%
Kanobana et al [17] Y Y + TQQ (Durkin et al, 1994) [43] – –
Neurologist; no EEG:
Andriantseheno et al [47] Y N + PAANS (2000) [41] 95% 65.10%
Avode et al [34] Y N + PAANS (2000) [41] 95% 65.10%
Christianson et al [48] Y N + + TQQ (Durkin, et al, 1994) [43] 100% 93%
Coleman et al [49] Y N + + Based on Placencia et al, 1992 [42] 98% 92%
Debrock et al [50] Y N + PAANS (1996) [51] 95% 65.10%
Dent et al [52] Y N + + PAANS (1996) [51] 95% 65.10%
Longe et al [53] Y N + Based on Osuntokun et al, 1987 [38] 91% 85%
Ngoungou et al [32] Y N + + PAANS (2000) [41] 95% 65.10%
Njamnshi et al [28] Y N + PAANS (2000) [41] 95% 65.10%
Rwiza et al [54] Y N + Based on Osuntokun et al, 1987 [38] 91% 85%
Winkler et al [55] Y N + + Based on Placencia et al, 1992 [42] 98% 92%
Yemadje et al [31] Y N + PAANS (2000) [41] 95% 65.10%
Dozie et al [56] Y N + Based on Shorvon & Farmer, 1988 [57] – –
Dumas et al [58] Y N + No details of questionnaire – –
Kaamugisha & Feksi [59] Y N + No details of questionnaire – –
Kabore et al [60] Y N + Based on Osuntokun et al, 1987 [38] – –
Kaiser et al [18] Y N + History taking (epilepsy in local language) – –
Case not confirmed by neurologist; no EEG:
Almu et al [61] N N + Based on Osuntokun et al, 1987 [38] 91% 85%
Birbeck et al [8] N N + Based on Placencia et al, 1992 [42] 98% 92%
Edwards et al [24] Notes 
only N + Two questions asked: convulsive seizure 
history, serious head injury 95% 52.30%
Goudsmit et al [62] N N + No details of questionnaire – –
Duggan [40] N N + No details of questionnaire – –
Nitiema et al [63] N N + PAANS (1996) [51] 95% 65.10%
Simms et al [39] N N + Based on Atijosan et al, 2007 [64] 99% 97%
N – no, Y – yes, PAANS – Pan African Association of Neurological Sciences, TQQ – Ten Questions' Questionnaire, GCAE – Global Cam-
paign Against Epilepsy, WHO – World Health OrganizationV
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Figure 4 Prevalence of active epilepsy by age: the size of the 
bubble is determined by the size of the sample for which the 
prevalence was calculated in original data, while the solid red 
data points represent the weighted mean of the prevalence for 
each 10–year age group, along with the error bars representing 
the 95% confidence intervals.
that age group. The size of the bubble is proportionate to 
the sample size for which the prevalence was calculated. 
There is a wide range of prevalence values, from 0/1000 to 
36/1000. The studies with larger population base mostly 
yield lower prevalence values. In addition, the sample size 
decreases as the mean age of the study population increas-
es. The solid pink data points represent the weighted mean 
of the prevalence for each 10–year age band. There is a 
peak of 11.6/1000 in the 20–29 age group, and a less pro-
nounced peak of 8.2/1000 in the 40–59 age group. From 
the calculated weighted mean of the prevalence for each 
age group, the number of people in each age group with 
active epilepsy was calculated. In total, 5.6 million people 
were estimated to have active epilepsy in SSA currently. Of 
this, the greatest number (1.7 million) of the cases was 
found in the 20–29 age group (Table 4).
Lifetime epilepsy in the population of SSA
In contrast to the bimodal nature of the prevalence trend 
seen in active epilepsy, prevalence of lifetime epilepsy peaks 
in the 20–29 age group (Figure 5) before decreasing to a 
plateau in the 40–59 age group, and then further decreas-
es in the 60+ age group. The number of people with life-
time epilepsy was calculated to be 7.0 million, with 2.7 
million in the 20–29 age group (Table 5).The prevalence 
ranged between 0/1000 and 33.5/1000. Larger studies, 
represented by larger circles in Figure 6, typically reported 
lower prevalence values, while higher prevalence values are 
mostly seen in smaller study populations.
Sex–specific patterns of prevalence
Figures 6 and 7 illustrate the pattern of prevalence by sex 
and age. The prevalence of active epilepsy among males 
and females is very similar for the 0–39 age groups, though 
Table 4 Calculated weighted mean of the prevalence of active 
epilepsy per age group and an estimated number of cases with 
active epilepsy in Sub-Saharan Africa in 2010
Age 
group 
(y)
Population 
of SSA in 
2010 (in 
thou-
sands)
Num-
ber of 
data 
points
Weighted mean 
of the prevalence  
(per 1000 
population) with 
uncertainty range 
(95% CI)
Estimated 
number of 
cases with 
active 
epilepsy
0–9 258 336 16 5.09 (3.27–6.91) 1 314 930
10–19 196 731 13 5.98 (0.92–11.04) 1 176 453
20–29 148 772 18 11.50 (7.29–15.71) 1 710 877
30–39 100 929 11 4.31 (0.00–9.05) 435 006
40–49 64 594 9 8.23 (2.82–13.64) 531 608
50–59 43 907 7 7.84 (3.65–12.03) 344 233
60+ 43 058 12 3.08 (0.43–5.73) 132 617
Total 856 327 5 645 723
y – years, CI – confidence interval
Table 5 Calculated weighted mean of the prevalence of lifetime 
epilepsy per age group and an estimated number of cases with 
lifetime epilepsy in Sub-Saharan Africa in 2010
Age 
group 
(y)
Population 
of SSA in 
2010 (in 
thou-
sands)
Num-
ber of 
data 
points
Weighted mean of 
the prevalence (per 
1000 population) 
with uncertainty 
range (95% CI)
Estimated 
number of 
cases with 
lifetime 
epilepsy
0–9 258 336 10 3.91 (0.00–14.85) 1 010 093
10–19 196 731 2 7.93 (6.36–9.50) 1 560 078
20–29 148 772 10 17.96 (8.29–27.63) 2 671 943
30–39 100 929 4 11.12 (5.46–16.78) 1 122 336
40–49 64 594 1 4.51 (N/A) 291 318
50–59 43 907 1 4.65 (N/A) 204 169
60+ 43 058 1 2.92 (N/A) 125 728
Total 856 327 6 985 666
y – years, CI – confidence interval, N/A – not applicable
Figure 5 Prevalence of lifetime epilepsy by age: the size of the 
bubble is determined by the size of the sample for which the 
prevalence was calculated in original data, while the solid 
orange data points represent the weighted mean of the preva-
lence for each 10–year age group, along with the error bars 
representing the 95% confidence intervals.V
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a noticeably higher prevalence of active epilepsy was ob-
served among women relative to men in the 40–59 age 
group (Figure 6). When the prevalence trend of lifetime 
epilepsy is analysed by sex, the peak in the 20–39 age 
group is higher for men, but the second peak in the 50–59 
age group is seen only in women (Figure 7). It is impor-
tant to note that data was not included in the above graphs 
from all studies as not all studies provided data for separate 
sexes, which explains differences in comparison to Figures 
4 and 5.
Seizure types
Online Supplementary Document shows the distribution 
of seizure types in the study groups for which the data were 
available, given that an individual may experience multiple 
seizure types. There was a predominance of generalised 
over partial seizures, with the most common generalised 
seizure type being tonic–clonic. Partial seizures made up 
36.3% of all seizures, with a large proportion of these de-
veloping into generalised seizures. Simple partial seizures 
were seen more often than complex seizures.
DISCUSSION
This paper sought to examine the prevalence trend of epi-
lepsy in SSA by age groups and sex. The prevalence of ac-
tive epilepsy can be seen to peak at two points across the 
lifespan: at age 20–29 and 40–59. The pattern of lifetime 
epilepsy also showed a peak in at age 20–29 but did not 
show a second peak. However, very few data were available 
for age 40 years and above, limiting the understanding of 
prevalence trends in older age groups. The peak in preva-
lence of active epilepsy seen in the 20–29 age group is sup-
ported by evidence in LMICs outside of SSA that saw sim-
ilar peaks in young adulthood [65,66]. Whilst many 
studies in high–income countries have observed bimodal 
distribution [67], a second peak in the 40–59 age group is 
rarely documented in LMICs. This may be due to the fact 
that LMIC populations tend to have lower mean ages, and 
therefore older age groups are less accessible to research 
studies. Furthermore, as fewer data points contribute to the 
calculation of the weighted mean of the prevalence the old-
er age groups, the second peak may be less reliable.
A total of 32 studies were suitable for inclusion from 18 
SSA countries, resulting in a limited evidence base from 
which to estimate epilepsy prevalence. The searches were 
limited to papers published post–1980. The number of 
studies conducted in the past decade suggests that research 
interest in epilepsy in SSA has increased over the past two 
decades. Publication bias, where researchers conduct stud-
ies in areas where they are aware of high prevalence or high 
levels of risk factors (eg, onchocerciasis), might have con-
tributed to an over estimation of the true prevalence.In 
contrast, stringent case definitions of active epilepsy (as 
having had a seizure in less than 5 years) in the majority of 
the studies could have resulted in an underestimation of 
the prevalence.
Door–to–door studies are considered to be the best avail-
able method for obtaining disease prevalence data. How-
ever, as there were not enough studies using the standard 
method, we also included the studies if they were popula-
tion based and did not rely on medical facilities or records, 
because it was assumed that a number of cases exist un-
known to the medical system [68]. This included cross–
sectional studies which relied on census data. One study 
was based in a school, and could have underestimated the 
epilepsy prevalence because related stigma and/or brain 
damage associated could have kept children out of main-
stream education. Furthermore, a variety of questionnaires 
and data collection methods have been used, which may 
have varied in accuracy for identifying cases of epilepsy. 
This is particularly relevant in epilepsy given the wide 
range of seizure types, some of which present vary differ-
ently to the stereotypical tonic–clonic seizure. A larger 
number of the studies took place in rural areas where ac-
curate records detailing the members of the populations 
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Figure 6 Weighted mean of the prevalence of active epilepsy per 
age group for men and women.
Figure 7 Weighted mean of the prevalence of lifetime epilepsy 
by sex and age group.V
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and where they live can be challenging. Furthermore, an 
address system may not be in place by which homesteads 
can by systematically visited. This may result in those con-
ducting the studies missing households located in more 
isolated areas.
Epilepsy diagnosis can be challenging as it relies on disease 
history recounted by individuals rather than definitive 
tests, leaving ample opportunities for misinterpretation of 
previous events (eg, interpreting fainting as epilepsy, failure 
to recognise more subtle forms of epilepsy such as absence 
seizures) or denial of having experienced or witnessed sei-
zures due to stigma [69]. As many people live in shared 
bedrooms in SSA [69], nocturnal seizures could have been 
witnessed and reported more accurately in history taking. 
As a recommendation for further epidemiological research, 
an increase in the number and size of population–based 
studies conducted in SSA would contribute to an estima-
tion of the prevalence of greater accuracy and reliability. It 
would be important that further studies be conducted in 
accordance with the criteria recommended in Table 6, so 
as to ensure that they reap accurate results and are suitable 
for inclusion in future systematic reviews.
The stigma associated with epilepsy in SSA has significant 
implications for the individual. In some communities, a 
seizure is seen as a sign that the individual is being, or has 
been possessed by spirits, resulting it hem either being 
viewed as dangerous or as powerful by those around them 
and themselves [70]. Furthermore, epilepsy is considered 
by some groups as infectious, with 40.6% of Tanzanian in-
dividuals involved in a study believing that epilepsy was 
infectious and could be spread through physical contact 
[71]. This may lead to those with epilepsy being ostracised 
from their community, with a likely impact on mental 
health as well as physical health if stigma prevents the re-
ceipt  of  medical  attention.  The  high  prevalence  of 
11.5/1000 for epilepsy in 20–29 year-olds in SSA may af-
fect whether women can marry and have children and 
whether they can fulfil their expected role in society. Fur-
thermore, it can impact on childcare with families strug-
gling to manage seizures or refusing to allow the child in 
public communal places with other family and village 
members. For men aged 20–29, they may find themselves 
excluded from manual labour or factory work because of 
the danger of injuries from machinery and fires. This has 
serious financial implications for the family and can lead 
to decreased socioeconomic status or even destitution [30]. 
The second prevalence peak affects individuals who are 
likely to be become grandparents and, given the epidemic 
of HIV in SSA increasing the number of grandparent care-
givers [72], this may result in a decreased level of care for 
children and limited finances available to cover the basic 
needs of the family.
The mission statement of the Global Campaign Against 
Epilepsy is “To improve acceptability, treatment, services 
and prevention of epilepsy worldwide” [73]. This paper 
highlights populations that are at risk of developing epi-
lepsy, and with whom treatment and prevention strategies 
should be focused. Given the wide range of environmental 
and genetic factors known to contribute to this prevalence, 
and their differing impact across time and place, it is clear 
that local, national and international policies are required 
to tackle this disease. Epilepsy care and treatment is likely 
to span a range of services from initial presentation of sei-
zures to putting in place a care plan and dealing with on-
going complications, and any treatment side effects. For 
this to be most effective, health services need to be inte-
grated. Given that seizures generally take place in the com-
munity and the likelihood of a seizure being witnessed by 
a health professional is small, it may be beneficial for health 
professionals to ask about seizure symptoms during con-
sultations with general patients. Furthermore, all health 
professionals must be trained in the recognition of the vary-
ing presentation of this population–spanning disease. By 
building the effectiveness of the formal and informal health 
service in dealing with epilepsy, it should be expected that 
improved management and treatment of the seizures will 
reduce the fear and stigma associated with them in the 
community. It may be helpful to work with traditional heal-
ers who may have greater contact with people with epilep-
sy than health services. Epilepsy awareness and education 
campaigns with an aim to decrease the stigma and discrim-
ination associated with epilepsy could provide more un-
derstanding of the nature of the disease especially in com-
munity  settings.  This  may  increase  the  readiness  of 
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Table 6 Criteria for retaining identified articles on epilepsy in 
Africa for further analysis
Criteria Minimum standard
Study method
A census should be conducted by the study team 
prior to the survey to establish the demograph-
ics of the study population. Door–to–door sur-
veys should be conducted. Known and potential 
risk factors in the area should be documented.
Case definition
ILAE – active epilepsy is defined as having had 
two or more seizure with at least one in the pre-
vious 5 y.
Population
Studies should include all age groups and be 
representative of the study population. Data 
should be presented in 10 y age bands (0–9 y, 
10–19 y, 20–29 y etc. until 60+) and be divided 
into males and females for each group to allow 
for comparisons between studies. Numerators 
and denominators should be available in addi-
tion to calculated prevalence.
Study size >1000
Mode of assessment
A standardised questionnaire should be admin-
istered by workers trained in identification of a 
history consistent with epilepsy, including be-
haviours or events that are likely to be consistent 
with seizure activity, frequency and duration of 
episodes.
ILAE – International League Against EpilepsyV
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individuals to admit to the condition and access treatment, 
while decreasing the negative reactions of those around 
them. Indeed, such campaigns also provide an opportu-
nity to educate the population regarding safety hazards in 
the home for people with epilepsy, such as stoves and fires. 
Programmes in Togo and Kenya, combining medical treat-
ment and psychosocial therapy, have achieved some suc-
cess in reintegrating people with epilepsy into society 
[74,75]. The impact of any policies developed should con-
tinually be evaluated to assess whether they are achieving 
their goals of reducing stigma, improving treatment access 
and ultimately decreasing prevalence.
CONCLUSION
Our study provided an estimate of the burden of epilepsy 
in Sub–Saharan Africa in the year 2010. It is likely to rep-
resent an underestimate of the true burden of the problem, 
because door–to–door studies are unlikely to recognize all 
forms of epilepsy, but rather only the most dramatic cases. 
More methodologically rigorous studies are needed in dif-
ferent parts of the SSA to improve estimates and for under-
standing the varying patterns of epilepsy by geographic 
location over time, and to inform policy more effectively. 
Moreover, trained health professionals and neurologists are 
in demand to provide more accurate diagnosis of epilepsy 
within this type of public health research, as well as pro-
vide care and treatment for people diagnosed. Reducing 
stigma could help improve diagnosis as it relies on disease 
history that many are ashamed to admit. Regardless of the 
limitations in the amount and quality of available informa-
tion, this study should help inform health policy and plan-
ning in efforts to tackle this important problem in low–re-
source settings.
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